NICE u-turn on Novartis’ migraine drug Aimovig
New analyses submitted by Novartis has helped to secure a NICE recommendation for NHS funding
Read More
Tag: Aimovig
New data back long-term use of Novartis’ Aimovig in migraine
The data add to real world and long-term evidence showing efficacy of Aimovig for migraine prevention across the migraine spectrum
Read More
NICE to request Aimovig evidence, appeal panel rules
NICE initially rejected NHS funding for the monoclonal antibody in January last year, deeming it “too costly” for the service.
Read More
Novartis’ Aimovig unlikely to be NHS funded for migraine
NICE has published final draft guidelines rejecting the drug in this setting
Read More
Novartis confirms long-term efficacy, safety of Aimovig
Back in April the SMC accepted the drug for use in patients with chronic migraine.
Read More
Aimovig shows long-term efficacy where other treatments fail
The STRIVE data will be presented at the European Academy of Neurology (EAN) annual meeting in Oslo, Norway.
Read More
Aimovig leads latest SMC decisions
Also mentioned were Eisai and MSD’s Lenvima and UCB’s Cimzia.
Read More
NICE says Novartis’ migraine drug Aimovig too costly for NHS
The National Institute for Health and Care Excellence (NICE) has rejected NHS funding for Novartis’ Aimovig (erenumab) as preventative treatment for migraine in draft guidelines.
Read More
Novartis’ Aimovig leads CHMP recommendations
The European Medicines Agency’s Committee for Medicinal Products for Human Use has endorsed nine medicines for approval at its May meeting, including Novartis’ Aimovig, the first human monoclonal antibody for migraine prevention.
Read More
US OK’s first-in-class drug Aimovig for migraine prevention
Amgen and Novartis’ Aimovig has become the first anti-CGRP therapy to win regulatory clearance in the US, winning approval for migraine prevention.
Read More
Amgen, Novartis’ migraine therapy impresses again
Amgen and Novartis’ closely watched experimental migraine therapy Aimovig has impressed again in late stage trials, this time hitting targets in patients for which other preventative treatments failed to work or weren’t tolerated.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
